Patient burden should be an early trial-design input, shaping visits, procedures, endpoints, recruitment, retention, and delivery feasibility.
“Patient-centricity” has become a common phrase in medtech.
But in clinical trial design, there is still a gap between talking about it and actually building studies around it.
Most device trials are understandably designed around endpoints, regulatory requirements, timelines, and operational feasibility. Patients are considered throughout the process, but they are not always the starting point for the design itself.
That distinction matters.
A patient-centric study is not simply one with more questionnaires or additional secondary endpoints. It starts with a different question:
What does participation realistically look like for the patient?
- How many visits are required?
- How burdensome are the procedures?
- How much disruption does the study create in day-to-day life?
Those considerations directly affect recruitment, retention, and execution quality. In practice, studies that are difficult for patients are usually difficult for sites and sponsors as well.
This is where many programs run into challenges. Patient-centric thinking is often introduced after the protocol has already taken shape. By then, the ability to make meaningful changes is limited.
The strongest trial designs account for patient burden much earlier. They treat it as a core design input rather than a late-stage refinement.
That changes decisions around visit schedules, assessments, endpoints, and follow-up requirements. It also tends to produce studies that are more feasible to execute and easier to sustain over time.
As evidence expectations continue to increase across medtech, patient-centric design is becoming less of a differentiator and more of a practical requirement.